Click to close

Contact us

Please complete the required fields.

*Required Fields

Send

US Toll-free: 1-888-286-4003 International: 1-978-347-1143 contact@visresearch.com

Click to close

Request a Demo

Please complete the required fields.

*Required Fields

Request a Demo

US Toll-free: 1-888-286-4003 International: 1-978-347-1143 contact@visresearch.com

Click to close

Report Problem

Please complete the required fields.

*Required Fields

Send

US Toll-free: 1-888-286-4003 International: 1-978-347-1143 contact@visresearch.com

Login

Click to close

Please complete the required fields.

Forgot your password? Register

Tell us your email address and we'll send you instructions on how to reset your password.

Click to close

Resolution not supported

Click to close

Saving...

 0%

Centro Respiratorio Quilmes

Hipolito Yrigoyen 856, Quilmes, Buenos Aires
B1878
Argentina
Website | ViS Profile

Center Profile Completeness

About
- Center
- Location
Infrastructure
- General
- Disease-Specific
Patients
- General
- Disease-Specific
Team
- Personnel
- Investigators
Expertise
- General
- Disease-Specific
Research
- Trials
- Publications
Network
- Disease-Specific

Trials in this area

- Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study (GlaxoSmithKline, SOLTI Breast Cancer Research Group, Breast International Group; NCT00553358; Year 2008)

- Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE) (Daiichi Sankyo Inc., Amgen; NCT01077154; Year 2010)

- Fixed Dose Combination Drug (Polypill)for Secondary Cardiovascular Prevention. (Mario Negri Institute for Pharmacological Research, Fundacion Clinic per a la Recerca Biomédica, Federación Argentina de Cardiología FAC, Instituto de Salud Carlos III, Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III, Rusculleda Foundation Instituto DAMIC, ARTTIC International Management Services, World Health Orga; NCT01321255; Year 2012)

- An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting (Parexel, Helsinn Healthcare SA; NCT01363479; Year 2011)

- A Study in Moderate to Severe Rheumatoid Arthritis Participants (Eli Lilly and Company; NCT01721057; Year 2012)

Diseases in this area

  • Rheumatoid Arthritis
  • Gout
  • Osteoarthritis
  • Inflammatory Polyarthropathies
  • Breast Cancer
  • Liver Cirrhosis
  • Non-Small Cell Lung (NSCLC)
  • Lung Cancer
  • Ischemic Heart Disease
  • Sarcoidosis
  • Heart Failure
  • Asthma
  • Herpes
  • Viral Infection
  • Viral Hepatitis B
  • COPD
  • Sleep Apnea
  • Anemia
  • Renal Failure
  • Viral Hepatitis
  • Viral Hepatitis C
  • Viral Hepatitis A
  • Sinusitis
  • Peripheral Vascular Disease
  • Osteoporosis
  • Diabetic Neuropathy
  • Renal Cancer
  • Menopause
  • Arterial Disorder, excl. Heart and CNS
  • Diabetes
  • Prostate Cancer
  • Congenital Cardiovascular Disorder
  • Pancreatic Cancer
  • Gastroesophageal Reflux Disease (GERD)
  • Arrhythmia
  • Uterine Cancer
  • Fluid, Electrolyte, Acid Balance Disorders
  • Cervical Cancer
  • Diseases of the Esophagus, Stomach and Duodenum
  • Pneumonia
  • Cancer of Digestive Organs
  • Ovarian Cancer
  • Bone Disorder, excl. Osteoporosis
  • Lower Respiratory Tract Infection
  • Hypercholesterolemia
  • Gastric/Esophageal Cancer
  • Dyslipidemia
  • Melanoma

Click to close
Click to close

Add to network